全文获取类型
收费全文 | 1816篇 |
免费 | 92篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 77篇 |
妇产科学 | 31篇 |
基础医学 | 170篇 |
口腔科学 | 45篇 |
临床医学 | 168篇 |
内科学 | 337篇 |
皮肤病学 | 24篇 |
神经病学 | 82篇 |
特种医学 | 671篇 |
外科学 | 98篇 |
综合类 | 45篇 |
预防医学 | 41篇 |
眼科学 | 6篇 |
药学 | 59篇 |
1篇 | |
肿瘤学 | 47篇 |
出版年
2023年 | 5篇 |
2022年 | 4篇 |
2021年 | 11篇 |
2020年 | 13篇 |
2019年 | 14篇 |
2018年 | 19篇 |
2017年 | 27篇 |
2016年 | 18篇 |
2015年 | 23篇 |
2014年 | 46篇 |
2013年 | 52篇 |
2012年 | 42篇 |
2011年 | 45篇 |
2010年 | 55篇 |
2009年 | 61篇 |
2008年 | 49篇 |
2007年 | 48篇 |
2006年 | 51篇 |
2005年 | 54篇 |
2004年 | 47篇 |
2003年 | 44篇 |
2002年 | 42篇 |
2001年 | 61篇 |
2000年 | 43篇 |
1999年 | 39篇 |
1998年 | 83篇 |
1997年 | 79篇 |
1996年 | 81篇 |
1995年 | 65篇 |
1994年 | 42篇 |
1993年 | 59篇 |
1992年 | 10篇 |
1991年 | 13篇 |
1990年 | 27篇 |
1989年 | 56篇 |
1988年 | 50篇 |
1987年 | 49篇 |
1986年 | 55篇 |
1985年 | 69篇 |
1984年 | 35篇 |
1983年 | 29篇 |
1982年 | 28篇 |
1981年 | 31篇 |
1980年 | 37篇 |
1979年 | 5篇 |
1978年 | 18篇 |
1977年 | 23篇 |
1976年 | 22篇 |
1975年 | 20篇 |
1969年 | 2篇 |
排序方式: 共有1912条查询结果,搜索用时 15 毫秒
71.
A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811 总被引:23,自引:13,他引:23
Larson RA; Dodge RK; Burns CP; Lee EJ; Stone RM; Schulman P; Duggan D; Davey FR; Sobol RE; Frankel SR 《Blood》1995,85(8):2025-2037
The goal of this phase II multicenter clinical trial was to evaluate a new intensive chemotherapy program for adults with untreated acute lymphoblastic leukemia (ALL) and to examine prospectively the impact of clinical and biologic characteristics on the outcome. One hundred ninety-seven eligible and evaluable patients (16 to 80 years of age; median, 32 years of age) received cyclophosphamide, daunorubicin, vincristine, prednisone, and L-asparaginase; 167 patients (85%) achieved a complete remission (CR), 13 (7%) had refractory disease, and 17 (9%) died during induction. A higher CR rate was observed in younger patients (94% for those < 30 years old, 85% for those 30 to 59 years old, and 39% for those > or = 60 years old, P < .001) and in those who had a mediastinal mass (100%) or blasts with a T-cell immunophenotype. Eighty percent of B-lineage and 97% of T-cell ALL patients achieved a CR (P = .01). The coexpression of myeloid antigens did not affect the response rate or duration. Seventy percent of those with cytogenetic or molecular evidence of the Philadelphia (Ph) chromosome and 84% of those without such evidence achieved a CR (P = .11). Patients in remission received multiagent consolidation treatment, central nervous system prophylaxis, late intensification, and maintenance chemotherapy for a total of 24 months. After a median follow-up time of 43 months, the median survival for all 197 patients is 36 months; the median remission duration for the 167 CR patients is 29 months. Favorable pretreatment characteristics relative to remission duration or survival are younger age, the presence of a mediastinal mass or lymphadenopathy, a white blood cell count (WBC) less than 30,000/microL, L1 morphology, T or TMy immunophenotype, and the absence of the Ph chromosome. The estimates of the proportion surviving at 3 years are 69% for patients less than 30 years old, 39% for those 30 to 59 years old, 89% for those who had a mediastinal mass, 59% with WBC less than 30,000/microL, 63% with L1 morphology, 69% for T or TMy antigen expression, and 62% for those who lack the Ph chromosome. Fifteen patients (8%) had no unfavorable prognostic factors and have an estimated probability of survival at 5 years of 100% (95% confidence interval, 77% to 100%). This intensive chemotherapy regimen produces a high remission rate and a high proportion of durable remissions in adults with ALL. 相似文献
72.
Dvorak AM; Tepper RI; Weller PF; Morgan ES; Estrella P; Monahan-Earley RA; Galli SJ 《Blood》1994,83(12):3600-3612
We used light and electron microscopy to analyze the eyelid inflammation that develops in transgenic mice that overexpress interleukin-4 (IL-4; Tepper et al, Cell 62:457, 1990). Analysis of alkaline Giemsa-stained plastic sections examined by light microscopy (Dvorak et al, J Exp Med 132:558, 1970), as well as by routine transmission electron microscopy, indicated that the mast cells in the inflammatory eyelid lesions were undergoing piecemeal degranulation, a form of secretion in which the cells' cytoplasmic granules exhibit characteristic morphologic changes that are thought to be associated with the prolonged, vesicle-mediated release of the granules' constituents. Moreover, by using a newly reported enzyme affinity-gold method, which stains histamine based on binding to diamine oxidase-gold (Dvorak et al, J Histochem Cytochem 41:787, 1993), we show that these activated mast cells had released much of their histamine content. The eyelid lesions also exhibited increased numbers of mast cells; interstitial fibrosis, particularly around cutaneous nerves and blood vessels; activated fibroblasts; focal axonal damage; venules with endothelial cells containing numerous vesiculo-vacuolar organelles; and infiltrates of neutrophils and eosinophils. Our findings illustrate that overexpression of the IL-4 gene in vivo can result in eyelid lesions associated with piecemeal degranulation of mast cells, as well as tissue fibrosis and a variety of other pathologic changes. These results also represent the first direct morphologic evidence for histamine secretion by mast cells in vivo. 相似文献
73.
Montes de Jesus F. M. Kwee T. C. Kahle X. U. Nijland M. van Meerten T. Huls G. Dierckx R. A. J. O. Rosati S. Diepstra A. van der Bij W. Verschuuren E. A. M. Glaudemans A. W. J. M. Noordzij W. 《European journal of nuclear medicine and molecular imaging》2020,47(3):529-536
European Journal of Nuclear Medicine and Molecular Imaging - Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after solid organ and hematopoietic stem cell... 相似文献
74.
Anniek KD Visser Nisha K Ramakrishnan Antoon TM Willemsen Valentina Di Gialleonardo Erik FJ de Vries Ido P Kema Rudi AJO Dierckx Aren van Waarde 《Journal of cerebral blood flow and metabolism》2014,34(1):118-125
The PET tracer [11C]5-hydroxytryptophan ([11C]5-HTP), which is converted to [11C]5-hydroxytryptamine ([11C]5-HT) by aromatic amino acid decarboxylase (AADC), is thought to measure 5-HT synthesis rates. But can we measure these synthesis rates by kinetic modeling of [11C]5-HTP in rat? Male rats were scanned with [11C]5-HTP (60 minutes) after different treatments. Scans included arterial blood sampling and metabolite analysis. 5-HT synthesis rates were calculated by a two-tissue compartment model (2TCM) with irreversible tracer trapping or Patlak analysis. Carbidopa (inhibitor peripheral AADC) dose-dependently increased [11C]5-HTP brain uptake, but did not influence 2TCM parameters. Therefore, 10 mg/kg carbidopa was applied in all subsequent study groups. These groups included treatment with NSD 1015 (general AADC inhibitor) or p-chlorophenylalanine (PCPA, inhibitor of tryptophan hydroxylase, TPH). In addition, the effect of a low-tryptophan (Trp) diet was investigated. NSD 1015 or Trp depletion did not affect any model parameters, but PCPA reduced [11C]5-HTP uptake, and the k3. This was unexpected as NSD 1015 directly inhibits the enzyme converting [11C]5-HTP to [11C]5-HT, suggesting that trapping of radioactivity does not distinguish between parent tracer and its metabolites. As different results have been acquired in monkeys and humans, [11C]5-HTP-PET may be suitable for measuring 5-HT synthesis in primates, but not in rodents. 相似文献
75.
76.
77.
78.
Parente Andrea de Vries Erik F. J. van Waarde Aren Ioannou Magdalini van Luijk Peter Langendijk Johannes A. Dierckx Rudi A. J. O. Doorduin Janine 《Molecular imaging and biology》2020,22(4):1012-1020
Molecular Imaging and Biology - Radiotherapy is a frequently applied treatment modality for brain tumors. Concomitant irradiation of normal brain tissue can induce various physiological responses.... 相似文献
79.
80.
CFAI‐Plus: Adding cognitive frailty as a new domain to the comprehensive frailty assessment instrument
下载免费PDF全文
![点击此处可从《International journal of geriatric psychiatry》网站下载免费的PDF全文](/ch/ext_images/free.gif)